@Zeus45 I read the study:
Anderson, R. A., Martin, C. W., Kung, A. W. C., Everington, D., Pun, T. C., Tan, K. C. B., … Baird, D. T. (1999). 7α-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men1. The Journal of Clinical Endocrinology & Metabolism, 84(10), 3556–3562. doi:10.1210/jcem.84.10.6028
It's well designed. It supports your point. It provides evidence that a 0.46 mg/d dose of MENT may optimally support sexual function (this is ~65%> the dose used in the trial that I cited where sexual function was suppressed).
It fails to demonstrate that MENT can supplant the function of 5α-reductase to support sexual function or that MENT supplants DHT's role, however.
This is because the dose trialled here does not abolish basal T secretion. Though the wash-out phase assured a hypogonadal state in all subjects (excellent), the MENT treatment arm subsequent to TE treatment saw subjects remain eugonadal (due to nadir T being maintained > 9 nmol/L), and the researchers acknowledge a positive mood effect due to carryover from >eugonadal nadir T concentrations.
Throughout all treatment phases, this low MENT dose (much lower than that used by bodybuilders/for muscle anabolism) fails to abolish endogenous T secretion.
This (well-designed) trial shows that MENT's androgenic effects and maintenance of sexual function is additive to the effects of DHT, that are amplified in 5α-reductase rich tissues by even low T secretion, and especially so in the MENT treatment arm subsequent to TE (where a carryover effect of >eugonadal nadir T concentrations have an acknowledged positive effect on mood).
It is my view that MENT doses used in practice by bodybuilders will not maintain sexual function without adjuvant use of androgen that provides for 5α-reductase function (or DHT, e.g., Andractim patch slapped on the testes), because these doses abolish endogenous T secretion.